ライフサイエンスコーパス: beta-cryptoxanthin

1 xcept for beta-carotene, alpha-carotene, and beta-cryptoxanthin).

2 s-lutein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin).

3 itamin C, alpha-carotene, beta-carotene, and beta-cryptoxanthin.

4 FEV(1)% after controlling for vitamin E and beta-cryptoxanthin.

5 r = 0.44 for beta-carotene, and r = 0.50 for beta-cryptoxanthin.

6 for lutein and 1.68 (95% CI: 0.99, 2.86) for beta-cryptoxanthin.

7 g beta-carotene, lutein, alpha-carotene, and beta-cryptoxanthin.

8 gest association was seen with vitamin E and beta-cryptoxanthin.

9 ved, with the highest increase in alpha- and beta-cryptoxanthin.

10 mic response and the colonic availability of beta-Cryptoxanthin.

11 rotenoids beta-carotene, alpha-carotene, and beta-cryptoxanthin.

12 90 (95% CI: 0.84, 0.96; P-trend < 0.001) for beta-cryptoxanthin.

13 hydroxy xanthophylls lutein, zeaxanthin and beta-cryptoxanthin.

14 nged from 0.03 for beta-carotene to 0.40 for beta-cryptoxanthin.

15 ns ranged from 0.13 for lycopene to 0.51 for beta-cryptoxanthin.

16 recursors alpha-carotene, beta-carotene, and beta-cryptoxanthin.

17 : alpha-carotene, 0.35; beta-carotene, 0.28; beta-cryptoxanthin, 0.35; lutein/zeaxanthin, 0.28; lycop

18 beta-carotene, 0.95 (95% CI: 0.70, 1.29) for beta-cryptoxanthin, 0.82 (95% CI: 0.60, 1.12) for lycope

19 6, 54.5, and 54.6 micro mol/L, respectively; beta-cryptoxanthin: 0.12, 0.16, and 0.16 micro mol/L, re

20 of lycopene (28%), lutein/zeaxanthin (17%), beta-cryptoxanthin (15%), total carotenoids (16%), serum

21 tene (5-fold), alpha-carotene (19-fold), and beta-cryptoxanthin (2-fold) concentrations; total-body v

22 w.) beta-carotene (29.4), zeaxanthin (1.28), beta-cryptoxanthin (2.8), phytoene (18.68) and phytoflue

23 carotene (1483%), alpha-carotene (145%), and beta-cryptoxanthin (67%) (P < or = 0.0001).

24 noid scores for other carotenoids, including beta-cryptoxanthin, alpha-carotene, and beta-carotene, w

25 D risk, whereas no association was found for beta-cryptoxanthin, alpha-carotene, and beta-carotene.

26 een plasma and BMC concentrations of lutein, beta-cryptoxanthin, alpha-carotene, and beta-carotene.

27 (phytoene, phytofluene, lutein, zeaxanthin, beta-cryptoxanthin, alpha-carotene, beta-carotene and ly

28 dinal association between serum carotenoids (beta-cryptoxanthin, alpha-carotene, beta-carotene, lutei

29 fold difference in beta-carotene relative to beta-cryptoxanthin and 36% of the variation and 4-fold d

30 and plasma and lipoprotein concentrations of beta-cryptoxanthin and alpha- and beta-carotene than did

31 Levels of lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in hexane extracts

32 onses were generated for lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in kaki, peach and

33 contributors to TEAC activity, while lutein, beta-cryptoxanthin and beta-carotene were primary contri

34 Other minor carotenoids were antheraxanthin, beta-cryptoxanthin and beta-carotene, while zeaxanthin w

35 eir levels were 15-fold higher than those of beta-cryptoxanthin and beta-carotene.

36 Recent epidemiological data on beta-cryptoxanthin and cardiovascular disease are lackin

37 g xanthophylls such as lutein, zeaxanthin or beta-cryptoxanthin and carotenes such as beta-carotene,

38 lower among women reporting intake values of beta-cryptoxanthin and lutein/zeaxanthin in the upper 2

39 ive oil) on the in vitro bioaccessibility of beta-Cryptoxanthin and phytosterols, a MFGM containing b

40 s between higher intake of beta-carotene and beta-cryptoxanthin and risk of hearing loss.

41 the antioxidants were modeled together, only beta-cryptoxanthin and supplemental zinc were statistica

42 ain antioxidant micronutrients, particularly beta-cryptoxanthin and supplemental zinc, and possibly d

43 -carotene, lycopene, lutein, zeaxanthin, and beta-cryptoxanthin and the risk of colon cancer.

44 ad negative associations with kidney stones: beta-cryptoxanthin and two forms of sphingomyelin.

45 In addition, beta-carotene, lutein, beta-cryptoxanthin and violaxanthin had also been quanti

46 amounts of mono-esterified lauric acid with beta-cryptoxanthin and with cryptocapsin.

47 Provitamin A carotenoids (beta-carotene and beta-cryptoxanthin) and capsanthin were present at highe

48 hyll concentrations (lutein + zeaxanthin and beta-cryptoxanthin) and hydrocarbon carotenoids (lycopen

49 otene, lutein plus zeaxanthin, lycopene, and beta-cryptoxanthin) and risk of HNC and HNC subtypes in

50 a-cryptoxanthin (standard hypocaloric diet + beta-cryptoxanthin), and control (standard hypocaloric d

51 beta-carotene, 0.91 (95% CI: 0.46, 1.81) for beta-cryptoxanthin, and 1.35 (95% CI: 0.68, 2.69) for lu

52 ed 2 wk apart were > or = 0.89 for lycopene, beta-cryptoxanthin, and alpha- and beta-carotene.

53 as assayed for ascorbic acid, beta-carotene, beta-cryptoxanthin, and alpha- and gamma-tocopherol.

54 ns of alpha-carotene, beta-carotene, lutein, beta-cryptoxanthin, and ascorbic acid increased by more

55 ed the oxidative cleavage of alpha-carotene, beta-cryptoxanthin, and beta-apo-8'-carotenal to yield r

56 Furthermore, the BA of lutein, beta-cryptoxanthin, and beta-cryptoxanthin esters was sh

57 r groups (13.0%, 17.4%, and 0.0% in HP-diet, beta-cryptoxanthin, and control groups, respectively; p

58 Higher intakes of beta-carotene, beta-cryptoxanthin, and folate, whether total or from di

59 n Americans had higher mean serum vitamin C, beta-cryptoxanthin, and lutein + zeaxanthin but lower fo

60 entrations of alpha-carotene, beta-carotene, beta-cryptoxanthin, and lutein+zeaxanthin were 0.25, 0.2

61 ncy and intakes of vitamin C, beta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food (P <

62 intakes of vitamins C and E, beta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food, or

63 intakes of vitamins C and E, beta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food: 0.2

64 of lycopene, alpha-carotene, beta-carotene, beta-cryptoxanthin, and lutein/zeaxanthin were similar i

65 predictors of beta-carotene, alpha-carotene, beta-cryptoxanthin, and lutein/zeaxanthin.

66 m alpha-carotene, beta-carotene, zeaxanthin, beta-cryptoxanthin, and lycopene.

67 Lycopene, beta-cryptoxanthin, and vitamin C were not associated wi

68 bstrate specificity and can esterify lutein, beta-cryptoxanthin, and zeaxanthin using multiple acyl d

69 uding alpha-carotene, beta-carotene, lutein, beta-cryptoxanthin, and zeaxanthin, showed no associatio

70 in respiratory health and that vitamin E and beta-cryptoxanthin appear to be stronger correlates of l

71 With the exception of this activity with beta-cryptoxanthin, BCO2 cleaves specifically at the 9'-

72 7 SU; 95% CI: 0.07, 0.28 SU; P = 0.005), and beta-cryptoxanthin (beta = 0.13 SU; 95% CI: 0.05, 0.21 S

73 s alpha-carotene (beta,epsilon-carotene) and beta-cryptoxanthin (beta,beta-carotene-3-ol), produces n

74 In general, beta-cryptoxanthin (betaCX) had higher retention than be

75 Synergistic relationships were observed for beta-cryptoxanthin concentration after irradiation.

76 ubject to between-subject variance ratio for beta-cryptoxanthin concentration was higher (0.23; 95% C

77 significantly lower plasma ascorbic acid and beta-cryptoxanthin concentrations than did nonsmokers an

78 Year 0 sum of provitamin A carotenoids and beta-cryptoxanthin concentrations were associated with m

79 There was a trend toward lower adjusted beta-cryptoxanthin concentrations with increasing level

80 A carotenoids, alpha- and beta-carotene and beta-cryptoxanthin, constituted 51% of median total caro

81 The potential of beta-cryptoxanthin (CX)-rich foods to form vitamin A (VA

82 e beta-Cryptoxanthin, tentatively identified beta-Cryptoxanthin esters and the ratio cis-/trans-beta-

83 e, the BA of lutein, beta-cryptoxanthin, and beta-cryptoxanthin esters was shown to be superior to th

84 h it is not present in the MS(2) spectrum of beta-cryptoxanthin esters.

85 In all acidic media, beta-cryptoxanthin exhibited the lowest degradation rate

86 ism to tailor asymmetric carotenoids such as beta-cryptoxanthin for vitamin A production.

87 ng grade 0 hepatic steatosis) in HP-diet and beta-cryptoxanthin group (82.6%) was also higher than ot

88 on-to-treat population (N = 92), HP-diet and beta-cryptoxanthin group experienced greater 12-week red

89 a-carotene, lycopene, lutein/zeaxanthin, and beta-cryptoxanthin, have been examined in a number of ep

90 ood levels that were 27% (lycopene) to 178% (beta-cryptoxanthin) higher than those of subjects in the

91 beta-Cryptoxanthin, however, undergoes an initial eccent

92 nd beta-cryptoxanthin (hypocaloric HP-diet + beta-cryptoxanthin), HP-diet (hypocaloric HP-diet + plac

93 randomized into 4 arms (n = 23): HP-diet and beta-cryptoxanthin (hypocaloric HP-diet + beta-cryptoxan

94 rotene, beta-carotene, lutein, lycopene, and beta-cryptoxanthin in 2 large cohorts.

95 The fatty acids esterifying beta-cryptoxanthin in mandarins were lauric, myristic, p

96 t of a hypocaloric HP-diet supplemented with beta-cryptoxanthin in NAFLD.

97 the effects of high protein (HP)-diet and/or beta-cryptoxanthin in non-alcoholic fatty liver disease

98 ticularly beta-carotene, alpha-carotene, and beta-cryptoxanthin, in both the supplemented and unsuppl

99 vely, and serum concentrations of lutein and beta-cryptoxanthin increased across the groups in a dose

100 association with beta-carotene, lutein, and beta-cryptoxanthin intakes were inverse but not signific

101 s from differential subcellular trafficking: beta-cryptoxanthin is transported to mitochondria via As

102 llows: beta-carotene < alpha-cryptoxanthin < beta-cryptoxanthin < lutein < zeaxanthin.

103 carotenoid peaks (alpha- and beta-carotene, beta-cryptoxanthin, lutein, and lycopene) plus alpha- an

104 major carotenoids (alpha- and beta-carotene, beta-cryptoxanthin, lutein, and lycopene), retinol, and

105 o had the lowest serum vitamin B-12, folate, beta-cryptoxanthin, lutein, and zeaxanthin concentration

106 e mass fraction of alpha- and beta-carotene, beta-cryptoxanthin, lutein, lycopene and zeaxanthin in m

107 carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein, lycopene and zeaxanthin) in

108 pha-carotene, beta-carotene, total carotene, beta-cryptoxanthin, lutein, lycopene, retinol, and ascor

109 lasma levels of antioxidants alpha-carotene, beta-cryptoxanthin, lutein/zeaxanthin, and lycopene were

110 carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, and lycopene) in

111 ficant associations of vitamin C, vitamin E, beta-cryptoxanthin, lutein/zeaxanthin, beta-carotene, an

112 vitamins C and E, retinol, and carotenoids (beta-cryptoxanthin, lutein/zeaxanthin, beta-carotene, an

113 ed intakes of alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, lycopene, folate,

114 85-1994, the carotenoids lutein, zeaxanthin, beta-cryptoxanthin, lycopene, alpha-carotene, and beta-c

115 Lutein, beta-cryptoxanthin, lycopene, alpha-carotene, retinol, a

116 ry intakes of beta-carotene, alpha-carotene, beta-cryptoxanthin, lycopene, and lutein + zeaxanthin an

117 carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein) and TB inciden

118 enoid intake (alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein+zeaxanthin) wit

119 ds, including alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein-zeaxanthin, blo

120 , high levels of circulating alpha-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin were

121 ing levels of alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin were

122 carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin) to

123 C, and E and alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin fro

124 lasma carotenoids (alpha- and beta-carotene, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin) we

125 etween plasma alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, lutein/zeaxanthin, retinol

126 for six weeks provoked an increment in serum beta-Cryptoxanthin of 38.9mug/dl (CI 95%; 31.0, 46.8; p<

127 beta carotene (OR, 0.91; 95% CI, 0.86-0.96), beta cryptoxanthin (OR, 0.91; 95% CI, 0.84-0.99), lutein

128 alpha-carotene, beta-carotene, lycopene, and beta-cryptoxanthin) or vitamin A after other potential r

129 (P = 0.002), beta-carotene (P < 0.001), and beta-cryptoxanthin (P < 0.001) concentrations.

130 ne (p < 0.001), 9.1 and 8.0 microg/liter for beta-cryptoxanthin (p < 0.001), and 50.6 and 46.8 microg

131 cents had higher alpha-carotene (P < 0.001), beta-cryptoxanthin (P < 0.001), and lutein and zeaxanthi

132 ren and adolescents had significantly higher beta-cryptoxanthin (P < 0.001), lutein and zeaxanthin (P

133 ds and carotenoid esters, beta-carotene, and beta-cryptoxanthin palmitate were the most abundant in p

134 he bioactive components (lutein, zeaxanthin, beta-cryptoxanthin, phytate, tannin and vitamin C) and c

135 s carotenoids (capsanthin, phytoene, lutein, beta-cryptoxanthin), polyphenols content (p-coumaric, fe

136 rotene (r = 0.40), beta-carotene (r = 0.28), beta-cryptoxanthin (r = 0.41), lutein (r = 0.23), and vi

137 enal were also consistently detected in BCO2-beta-cryptoxanthin reaction mixtures.

138 Auroxanthin and beta-cryptoxanthin represented around 50% of total carot

139 s-lutein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin, respectively.

140 beta-carotene, lycopene, lutein, zeaxanthin, beta-cryptoxanthin), retinol, and tocopherols (alpha-toc

141 beta-carotene, lycopene, lutein, zeaxanthin, beta-cryptoxanthin, retinol, alpha-tocopherol, gamma-toc

142 while there was an inverse association with beta-cryptoxanthin (RR = 0.59, 95% CI: 0.39, 0.90; p-tre

143 A hypocaloric HP-diet supplemented with beta-cryptoxanthin safely and efficaciously improves NAF

144 dney stones in both HPFS and NHS II cohorts: beta-cryptoxanthin, sphingomyelin (d18:2/24:1, d18:1/24:

145 n), HP-diet (hypocaloric HP-diet + placebo), beta-cryptoxanthin (standard hypocaloric diet + beta-cry

146 ted orange hybrid maize; lutein, zeaxanthin, beta-cryptoxanthin, tannin and vitamin C increased with

147 In faeces, free beta-Cryptoxanthin, tentatively identified beta-Cryptoxa

148 st categories of intake ranged from 0.80 for beta-cryptoxanthin to 0.89 for alpha-carotene and lutein

149 alpha-carotene, beta-carotene, lycopene, and beta-cryptoxanthin), vitamin A, and retinol were not ass

150 beta-carotene, lutein/zeaxanthin, lycopene, beta-cryptoxanthin, vitamin A, serum beta-carotene, and

151 as 0.17, which is in line with the fact that beta-cryptoxanthin was mostly esterified and not free (u

152 A decrease of beta-cryptoxanthin was observed at higher temperatures,

153 provitamin A carotenoids, beta-carotene, and beta-cryptoxanthin were each inversely associated with a

154 one standard deviation of serum vitamin E or beta-cryptoxanthin were equivalent to the negative influ

155 As for FEV(1)%, vitamin E and beta-cryptoxanthin were most strongly related to FVC% wh

156 and dietary intakes of lutein+zeaxanthin and beta-cryptoxanthin were not associated with breast cance

157 Although the pooled RRs for quintile 5 for beta-cryptoxanthin were not significant, inverse trends

158 genated carotenoids (lutein, zeaxanthin, and beta-cryptoxanthin) were detected at electrical potentia

159 nd 7-cis isomers, cis anhydrolutein, and cis beta-cryptoxanthin) were inversely associated with 15-F(

160 tiate between the esters of zeinoxanthin and beta-cryptoxanthin, which were undifferentiated to date

161 ange xanthophylls (cis-violaxanthin, lutein, beta-cryptoxanthin, zeaxanthin and cis-antheraxanthin) w